Abstract
Group B Streptococcal (GBS), a gram-positive Streptococcus, is one of the important pathogenic bacteria which can causes neonatal sepsis and meningitis. The main measure of GBS is intrapartum antibiotics prevention (IAP), which plays an important role in early-onset GBS disease (GBS-EOD), but remains a high infection rates in late-onset GBS disease(GBS-LOD). What′s more, with the extensive use of antimicrobial drugs, the GBS drug resistance rate increased gradually. So that GBS vaccines provide a new method to prevent neonatal GBS infection, especially the capsular polysaccharide conjugate vaccine, the phase Ⅰ and Ⅱ clinical trials have been completed, and the protective antibody levels has been researching. This research will focus on the research progress on GBS vaccines in order to provide reference for further development of GBS vaccines. Key words: Streptococcus agalactiae; Infection; Vaccines; Antibodies
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
